Main Menu

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor, alpha chain) (clone 3C7) as described in J Immunol. 1984 Oct;133(4):1970-5 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor) (clone 7D4) as described in Proc Natl Acad Sci U S A. 1983 Sep;80(18):5694-8 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD69 (early activation marker) (clone H1.2F3) as described in J Immunol. 1988 Jul 15;141(2):369-76 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse Ly-6A/E (Sca-1) (clone D7) as described in J Immunol. 1986 Nov 15;137(10):3240-6 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD90 (Thy-1) (clone G7) as described in J Exp Med. 1984 Mar 1;159(3):716-30 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication.

Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.

Aldehyde dehydrogenase enzymes (ALDHs) have a broad spectrum of biological activities through the oxidation of both endogenous and exogenous aldehydes. Unbalanced biological activity of ALDHs has been associated with a variety of disease states such as alcoholic liver disease, Parkinson’s disease, obesity, and Cancer. Increased expression of ALDH1A1 has been identified in a wide-range of human cancer stem cells and is associated with cancer relapse and poor prognosis, raising the potential of ALDH1A1 as a therapeutic target.

Rotaviral infection is the most common gastrointestinal illness of children in the world, affecting both developed and developing economies. There is no specific drug treatment for rotavirus infection. Vaccination and good hygiene are key to prevention.